8C5 Stock Overview
A biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Coherus BioSciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.61 |
| 52 Week High | US$4.94 |
| 52 Week Low | US$1.43 |
| Beta | 0.66 |
| 11 Month Change | -5.53% |
| 3 Month Change | -26.61% |
| 1 Year Change | -57.51% |
| 33 Year Change | -86.55% |
| 5 Year Change | -92.14% |
| Change since IPO | -86.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8C5 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 8.4% | -0.5% | 0.8% |
| 1Y | -57.5% | -18.9% | 2.0% |
Return vs Industry: 8C5 underperformed the German Biotechs industry which returned -18.6% over the past year.
Return vs Market: 8C5 underperformed the German Market which returned 3.1% over the past year.
Price Volatility
| 8C5 volatility | |
|---|---|
| 8C5 Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 8C5's share price has been volatile over the past 3 months.
Volatility Over Time: 8C5's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 249 | Denny Lanfear | www.coherus.com |
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME.
Coherus BioSciences, Inc. Fundamentals Summary
| 8C5 fundamental statistics | |
|---|---|
| Market cap | €182.06m |
| Earnings (TTM) | -€55.35m |
| Revenue (TTM) | €281.80m |
0.7x
P/S Ratio-3.3x
P/E RatioIs 8C5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8C5 income statement (TTM) | |
|---|---|
| Revenue | US$301.87m |
| Cost of Revenue | US$176.70m |
| Gross Profit | US$125.17m |
| Other Expenses | US$184.46m |
| Earnings | -US$59.29m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.52 |
| Gross Margin | 41.46% |
| Net Profit Margin | -19.64% |
| Debt/Equity Ratio | -580.0% |
How did 8C5 perform over the long term?
See historical performance and comparison